Singular Genomics Systems, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Singular Genomics Systems (Nasdaq: OMIC) is set to showcase the G4 Sequencing Platform at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 1:30 p.m. PT.

The event will be held virtually, allowing investors to access the presentation via a live and recorded webcast on the company's investor relations website. Singular Genomics focuses on advancing genomics through innovative next-generation sequencing (NGS) and multiomics technologies, with a mission to enhance scientific and medical advancements.

Management to Discuss the Launch of the G4 Sequencing Platform

LA JOLLA, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present virtually at the 40^th Annual J.P. Morgan Healthcare Conference.

Singular Genomics’ management is scheduled to present virtually on Wednesday, January 12, 2022 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors and other interested parties are invited to listen to a live and recorded webcast of the presentation on the News & Events section of the company’s investor relations website at https://investor.singulargenomics.com/news-events/event-calendar.

About Singular Genomics Systems, Inc.
Singular Genomics is a life science technology company that is leveraging novel, next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians. Our mission is to accelerate genomics for the advancement of science and medicine. Our Singular Sequencing Engine is the foundational platform technology that forms the basis of our products in development as well as our core product tenets: accuracy, speed, flexibility and scale. We are currently developing two integrated solutions that are purpose built to target applications in which these core product tenets matter most. Our first integrated solution, the G4, is targeted at the NGS market. Our second integrated solution in development, the PX Integrated Solution, combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument to offer a versatile multiomics solution. The G4 and PX Integrated Solutions are both comprised of an instrument and an associated menu of consumable kits.

Investor Contact
Matt Clawson
949-370-8500
ir@singulargenomics.com

Media Contact
Dan Budwick, 1AB
973-271-6085
dan@1abmedia.com

FAQ

When is the J.P. Morgan Healthcare Conference presentation by Singular Genomics?

Singular Genomics will present on January 12, 2022, at 1:30 p.m. Pacific Time.

What will Singular Genomics discuss at the conference?

The company will discuss the launch of its G4 Sequencing Platform.

How can investors listen to the presentation by Singular Genomics?

Investors can access a live and recorded webcast on the company's investor relations website.

What technologies does Singular Genomics leverage?

The company leverages next-generation sequencing (NGS) and multiomics technologies.

What are the core product tenets of Singular Genomics?

The core product tenets include accuracy, speed, flexibility, and scale.